

Special Issue

Chimeric Antigen Receptor T-Cell Therapy

Message from the Guest Editor

CAR T cell therapy with two commercial products recently came into clinical practice both in the US and Europe. Hematologists and oncologists are getting more and more familiar with the potential of CAR T cell therapy, its effectiveness, and side effects. Clinical practice taught us that therapy is safe when physicians and nurses are well-prepared and instructed in the classification of side effects as well as in therapeutic algorithms. The clinical effectiveness of CAR T cells depends on tumor size, number and functionality of cells, and the therapy line in which CAR T cell therapy is employed. Every day, we are discovering new aspects of CAR T cell therapy and that we need new tools and algorithms to make CAR T cell therapy more effective. Additionally, the entire process is translational: Clinicians have to learn from researchers and vice versa. That sparks new excitement and enthusiasm. The aim of this Special Issue is to address preclinical, translational, and clinical aspects of current CAR T cell therapy for researchers and clinicians working in the field.

Guest Editor

Prof. Dr. Michael Schmitt

1. Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany
2. German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany

Deadline for manuscript submissions

closed (30 April 2020)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/30967

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/

[cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).